Generate Biomedicines, Inc. (GENB) stock
GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$10.38+0.54 (+5.49%)
Close on Nov 18, 2026Market cap $1.33BP/E –Yield –
Generate Biomedicines revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.22M | -58.3% |
| Q2 FY2026 | Jun 30, 2026 | $6.31M | -28.4% |
| Q1 FY2026 | Mar 31, 2026 | $7.22M | – |
| Q3 FY2025 | Sep 30, 2025 | $9.63M | – |
| Q2 FY2025 | Jun 30, 2025 | $10.13M | – |
| Q1 FY2025 | Mar 31, 2025 | $8.82M | – |
See a number that looks wrong?